quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

JPMorgan Says Lamb Weston Holdings (LW) Q3 Results Were Better Than Feared

View original at finance.yahoo.com
JPMorgan Says Lamb Weston Holdings (LW) Q3 Results Were Better Than Feared Lamb Weston Holdings, Inc. (NYSE:LW) is one of the 10 Best Stocks That Beat Earnings Estimates…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The quarter was supported by continued strength in North America and disciplined execution, while highlighting ongoing efforts to align supply and demand and manage a competitive international environment

    60% confidence

  • Certain AI stocks offer greater upside potential and carry less downside risk than Lamb Weston

    60% confidence

  • JPMorgan maintained a Neutral rating on Lamb Weston shares

    60% confidence

  • Lamb Weston delivered a Q3 EPS beat, driven by stronger-than-expected performance in North America that offset international weakness, higher interest expense, and tax impacts

    60% confidence

  • The outlook reflects currency benefits, tariff impacts, ongoing disruption in parts of the Middle East, and the inclusion of a 53rd week in fiscal 2026

    60% confidence

  • The results were better than feared, noting the company narrowed its full-year EBITDA guidance while raising the midpoint, signaling stabilization in North America alongside more predictable international pressures

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
JPMorgan Says Lamb Weston Holdings (LW) Q3 Results Were Better Than Feared — Source | Via News | pt.VIA.NEWS